Inspire Medical Systems (NYSE:INSP) Given New $66.00 Price Target at Jefferies Financial Group

Inspire Medical Systems (NYSE:INSP) had its target price cut by Jefferies Financial Group from $81.00 to $66.00 in a report published on Thursday morning,Benzinga reports. They currently have a hold rating on the stock.

Other equities analysts have also recently issued research reports about the company. JPMorgan Chase & Co. boosted their price objective on Inspire Medical Systems from $82.00 to $118.00 and gave the company a “neutral” rating in a report on Tuesday, December 16th. Royal Bank Of Canada decreased their price target on Inspire Medical Systems from $90.00 to $68.00 and set a “sector perform” rating for the company in a report on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Inspire Medical Systems in a research note on Monday, December 29th. Mizuho cut their target price on shares of Inspire Medical Systems from $130.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday. Finally, KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, November 4th. Six analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $110.65.

Inspire Medical Systems Stock Down 12.4%

Shares of Inspire Medical Systems stock opened at $59.74 on Thursday. The company has a market cap of $1.74 billion, a P/E ratio of 12.00, a PEG ratio of 6.88 and a beta of 0.74. The firm’s 50 day moving average price is $94.42 and its 200-day moving average price is $91.48. Inspire Medical Systems has a 52-week low of $53.11 and a 52-week high of $197.75.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.96. Inspire Medical Systems had a return on equity of 11.47% and a net margin of 15.95%.The company had revenue of $269.08 million for the quarter, compared to analyst estimates of $264.02 million. During the same period in the prior year, the company posted $1.15 EPS. The firm’s quarterly revenue was up 12.2% compared to the same quarter last year. As a group, equities research analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the sale, the director owned 26,046 shares in the company, valued at $3,320,344.08. This represents a 7.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Inspire Medical Systems

Hedge funds have recently added to or reduced their stakes in the stock. Manning & Napier Advisors LLC acquired a new position in Inspire Medical Systems during the third quarter worth $32,000. CWM LLC increased its position in shares of Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after acquiring an additional 242 shares in the last quarter. Havemeyer Place LP purchased a new stake in Inspire Medical Systems during the 4th quarter worth $39,000. V Square Quantitative Management LLC purchased a new position in Inspire Medical Systems in the fourth quarter valued at about $40,000. Finally, Larson Financial Group LLC grew its stake in shares of Inspire Medical Systems by 21,266.7% in the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after buying an additional 638 shares in the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 results beat and operational strength — Inspire posted $269.1M in Q4 revenue (↑12% y/y) and adjusted EPS of $1.65, topping estimates; gross margin expanded and operating cash flow and buybacks support cash returns. Earnings Release
• Neutral Sentiment: Full earnings package and call are available for deeper read — slide deck and transcript provide detail on assumptions behind the 2026 outlook and tax/adjustment impacts for modeling. Slide Deck / Press Release Call Transcript
• Negative Sentiment: Guidance cut and coding/reimbursement uncertainty — management narrowed FY2026 revenue to $950M–$1.0B and said the Inspire V procedure will likely transition to CPT 64582 with a -52 modifier, potentially lowering physician reimbursement and pressuring procedure volumes. That guidance revision is the primary driver of the selloff. MSN: Revenue Outlook & Coding
• Negative Sentiment: Immediate market reaction — analysts and headlines highlighted the coding/guidance risk and shares fell sharply despite the beat. Zacks: Stock Falls Despite Q4 Beat Investing.com: Shares Slide
• Negative Sentiment: Analyst price-target resets — multiple firms lowered targets (Jefferies to $66, Truist to $70, Mizuho to $85, Piper Sandler to $85) which increases near-term downside pressure even when some ratings remain constructive. Benzinga: Analyst Actions The Fly: Mizuho PT Cut
• Negative Sentiment: Bearish analysis and investor concerns — independent commentary highlights lingering risks around reimbursement, growth cadence and margin sustainability, reinforcing the negative sentiment. Seeking Alpha: Critical Take

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.